MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202421100525 A) filed by Omgene Life Sciences Pvt. Ltd on January 18, 2025, for “a Stable Novel Formulation Of Glucagon-Like Peptide-1 Receptor Agonist And Process Thereof”.
Inventors include Dr. A L Prasad; Shashikant J. Nandanikar; Nimisha B. Kalal; Shubhangi K. Dhariya; and Azra K. Kagdi.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: The present invention pertains to stable pharmaceutical tablet formulations intended for oral intake, containing Semaglutide, one or more permeation enhancers and pharmaceutically acceptable excipients. These formulations are designed to improve the absorption of Semaglutide when taken orally, suitable for the treatment of type 2 diabetes. The invention also includes a method for preparing these formulations.
Disclaimer: Curated by HT Syndication.
